Breast cancer is considered advanced if it has spread beyond the breast. If you have advanced breast cancer, you may be eligible for the following clinical trial offered at Albert Einstein Cancer Center:

BP-58

BP-58 is a study that will evaluate the effectiveness of the combination of three chemotherapy drugs in patients with metastatic or locally advanced breast cancer. The drugs being evaluated in BP-58 are adriamycin (doxorubicin), taxotere (docetaxel) and cyclophosphamide.

Women with stage IIIB or IV breast cancer may be eligible for the study. Women with stage IIIB and IV breast cancer may include:

• women who are experiencing a recurrence of breast cancer;
• women who have breast cancer that has spread beyond the breast and lymph nodes; and
• women with inoperable breast cancer.
  

Previous studies have shown that chemotherapy treatments can reduce the size and improve control of stage IIIB and IV breast cancers.

The purpose of BP-58 is to study how stage IIIB and IV breast cancer responds to treatment with doxorubicin and cyclophosphamide when a third drug, docetaxel, is added to the treatment regimen. All three are already FDA approved and commonly used for the treatment of breast cancer.

BP-58 is a study of the National Surgical Adjuvant Breast and Bowel Project (NSABP).

For more information, please call (215) 456-7215.

Back to Breast Cancer Studies